Symptom Cluster Presented by Non-small Cell Lung Cancer Patients on Gefitinib Treatment.
- Author:
Sung Young LEE
1
;
Hyeoun Ae PARK
Author Information
1. National Cancer Center, Goyang, Korea. ernestoche@ncc.re.kr
- Publication Type:Original Article
- Keywords:
Symptom;
Cluster;
Gefitinib;
Lung cancer;
Quality of life
- MeSH:
Anorexia;
Carcinoma, Non-Small-Cell Lung;
Constipation;
Cough;
Dyspnea;
Fatigue;
Humans;
Lung Neoplasms;
Mothers;
Quality of Life;
Quinazolines
- From:Journal of Korean Oncology Nursing
2009;9(2):77-85
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The purpose of this study was to identify symptom cluster experienced by patients with advanced non-small cell lung cancer (NSCLC) on gefitinib treatment. In addition, this study assessed the patterns in severity of the symptom cluster and differences in quality of life (QOL) and function among subgroups by the severity of symptom cluster. METHODS: This study was conducted as a secondary analysis of symptoms of 72 patients from a mother study. Factor analysis was used to identify symptom clusters measured with EORTC QLQ-C30 and LC13 symptom related items. RESULTS: Three symptom clusters were identified: cluster 1 was comprised of fatigue, anorexia and dysphagia; cluster 2 of dyspnea, cough and insomnia; and cluster 3 of pain, constipation and nausea/vomiting. These three symptom clusters were improved one week after gefitinib administration. The group with more severe symptom clusters showed significantly lower QOL and function than the group with less severe symptom clusters. CONCLUSION: Since symptom clusters experienced by the patients with advanced NSCLC influenced on the QOL and function, it is important for nurses to understand and observe their symptom clusters. In addition, there is an necessity to develop nursing interventions to effectively care patients with the symptom clusters.
